ReviewMedical gas research2026
Hydrogen: a novel strategy for preventing and treating hearing loss.
Review in Medical gas research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sensorineural hearing loss, often caused by irreversible damage to cochlear hair cells, is primarily mediated by oxidative stress triggered by aging, noise exposure, or ototoxic agents. Conventional treatments such as hearing aids or cochlear implants have limitations in accessibility and efficacy. Hydrogen (H 2 ), a selective antioxidant with anti-inflammatory and anti-apoptotic properties, has demonstrated protective effects on various organ systems. This review evaluates the therapeutic potential of H 2 in preventing and treating sensorineural hearing loss and aims to inform future research directions. In preclinical models of sensorineural hearing loss, H 2 administration via inhalation, injection, or drinking water reduces reactive oxygen species accumulation, protects cochlear hair cells, and improves functional hearing markers (auditory brainstem response and distortion product otoacoustic emission). Clinical trials have shown that H 2 inhalation improves hearing thresholds in patients with radiotherapy-induced hearing loss and idiopathic sudden sensorineural hearing loss. No serious side effects have been observed. H 2 's high diffusion capacity and selective reactive oxygen species-scavenging properties support its role as a promising therapeutic for sensorineural hearing loss. While animal data are robust and initial clinical outcomes encouraging, further large-scale studies are warranted to validate efficacy, optimize delivery methods, and establish clinical protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.